Idexx Laboratories (IDXX) reported $901.6 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 8.8%. EPS of $2.32 for the same period compares to $2.05 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $888.73 million, representing a surprise of +1.45%. The company delivered an EPS surprise of +9.43%, with the consensus EPS estimate being $2.12.While investors scrutinize revenue and earnings changes year-over-year and how they compare wi ...

Idexx Laboratories (IDXX) came out with quarterly earnings of $2.32 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $2.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.43%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $2.37 per share when it actually produced earnings of $2.53, delivering a surprise of 6.75%.Over t ...

Investors are always looking for stocks that are poised to beat at earnings season and IDEXX Laboratories, Inc. (IDXX) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because IDEXX Laboratories is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is ...

Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Idexx Laboratories (IDXX) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revi ...

Wall Street analysts forecast that Idexx Laboratories (IDXX) will report quarterly earnings of $2.12 per share in its upcoming release, pointing to a year-over-year increase of 3.4%. It is anticipated that revenues will amount to $890.61 million, exhibiting an increase of 7.5% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have r ...

IDEXX Laboratories, Inc. (IDXX) is likely to grow in the coming quarters, backed by the sustained success of CAG’s recurring diagnostic products and services. A key element of IDEXX’s customer engagement strategy is the expansion of its commercial footprint in a disciplined approach. Robust demand for the company’s cloud-based offerings buoys optimism.However, negative solvency and foreign exchange fluctuations are discouraging for the company’s operations.In the past year, this Zacks Rank #3 (Hold) stock h ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Idexx Laboratories (IDXX) , which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider.This Animal diagnostic and health care company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 8.3 ...

IDEXX Laboratories, Inc. (IDXX) is set to release fourth-quarter 2023 results on Feb 5 before the opening bell.The company posted adjusted earnings per share (EPS) of $2.53 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 6.8%. IDEXX Laboratories beat earnings estimates in all the trailing four quarters, the average surprise being 7.64%.Let’s look at how things have shaped up before this announcement.Factors at PlayIDEXX’s Companion Animal Group (“CAG”) Diagnostics recurring rev ...

IDEXX Laboratories, Inc. (IDXX) recently expanded its Fecal Dx antigen testing platform with the addition of Cystoisospora —  a common intestinal parasite that is the source of diarrhea, weight loss and dehydration — primarily in young dogs and cats. Fecal Dx antigen testing with Cystoisospora will be offered at IDEXX Reference Laboratories in March in North America and globally in third-quarter 2024.The recent development will bolster IDEXX’s Livestock, Poultry and Dairy (LPD) business.More on Fecal Antige ...

Fecal Dx antigen testing will soon detect the most common intestinal parasites earlier, uncovering more infectionsWESTBROOK, Maine, Jan. 12, 2024 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced the expansion of its Fecal Dx® antigen testing platform with the addition of Cystoisospora, a common intestinal parasite that causes diarrhea, weight loss, and dehydration, primarily in young dogs and cats. IDEXX's Fecal Dx antigen testing offers earlie ...